Medical Device Legal News with Sam Bernstein: Episode 11
A Conversation With NAAG Executive Director Brian Kane - Regulatory Oversight Podcast
Podcast: The Briefing by the IP Law Blog - Chipotle and Sweetgreen Settle Food Fight Over CHIPOTLE Trademark
The Briefing by the IP Law Blog: Chipotle and Sweetgreen Settle Food Fight Over CHIPOTLE Trademark
The Justice Insiders Podcast: Feds Danske to a New Tune
State AG Pulse | Money, Money, Money: Where does it go and why?
The Chartwell Chronicles: Occupational Exposure Claims
The Chartwell Chronicles: An Overview of New Jersey Workers' Compensation
Patient Steering and Charting
A Look at the Unique Features of State AG Investigations and What Companies Should Consider in Selecting Outside Counsel - Regulatory Oversight Podcast
A Close Look at the Justice Department’s Settlement with Meta (Formerly Facebook) to Resolve Alleged Fair Housing Act Violations Arising from Meta’s Targeted Advertising System
Settlement and Mediation Strategy
An Overview of South Carolina Workers' Compensation
An Overview of New Jersey Workers' Compensation
Protecting Trade Secrets When Facing Lawsuits or Alternative Dispute Resolution Procedures
No Harbor is Limitless: Restrictions of the Federal Anti-Kickback Statute's Safe Harbor Provisions
Episode 149 -- A Deep Dive into Alexion's SEC Settlement for FCPA Violations
Developments in New York State Labor and Employment Law – What You Need to Know in 2020
DOL Sets Enforcement Records Again - Employment Law This Week® - Trending News
Jones Day Presents: Large Business & International Examination Strategies: Fast Track Settlements
Second Circuit Affirms “Pay for Delay” Dismissal: On May 13, 2024, the Second Circuit affirmed dismissal of antitrust claims brought by wholesalers, retailers, and employee benefit funds that alleged they overpaid for the...more
Please see full Chart below for more information....more
On November 15, the FDA approved Pfizer’s Humira® biosimilar, ABRILADA (adalimumab-afzb). The acting director of the Office of Therapeutic Biologics and Biosimilars in the FDA’s Center for Drug Evaluation and Research, Sarah...more